Venus Remedies

The QIDP designation provides regulatory benefits, advancing efforts to combat antimicrobial resistance

Venus Remedies will test APC-148 in combination with various antibiotics against its extensive library of clinical isolates…

The global Sugammadex market, valued at approximately 1.53 billion in 2023, is projected to grow at a CAGR of 8.5 per cent,…

On an exclusive licensing agreement, Venus Remedies will lead clinical trials and commercialisation of MET-X to combat…

Approval expands company’s footprint in Southeast Asia’s growing anticoagulant market

Akshansh Chaudhary, Executive Director & Chief Technical Officer, Venus Remedies highlights the challenges SMEs face and how…

This renewal is applicable to the company's manufacturing facility for Cephalosporin, Carbapenem, and Oncology (Liquid and…

The Europe carbapenem market generated revenue of $ 1,061.4 million in 2022 and is expected to grow at a CAGR of 4 per cent from…

Initiative aimed at enhancing workforce skills and competency in line with industry standards to create a talented workforce for…

Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre explains strategies to…